Alkermes Plc

Healthcare · Drug Manufacturers - Specialty & Generic

42.10$ -2.7% vs. previous close Closing price · As of: Sep 23, 2026

Statements

Income Statement

Alkermes Plc (ALKS) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Revenue" came in at 496 million $. Tick rows to compare them in a chart.

Income Statement Balance Sheet Cash Flow Ratios

Annual Quarterly

Amounts Change % Common size % Per share

Last 12 Full history

Download as CSV

Tick rows to compare them in a chart (up to 4)

Income Statement ALKS
Line item	Q3 16	Q4 16	Q1 17	Q2 17	Q3 17	Q4 17	Q1 18	Q2 18	Q3 18	Q4 18	Q1 19	Q2 19	Q3 19	Q4 19	Q1 20	Q2 20	Q3 20	Q4 20	Q1 21	Q2 21	Q3 21	Q4 21	Q1 22	Q2 22	Q3 22	Q4 22	Q1 23	Q2 23	Q3 23	Q4 23	Q1 24	Q2 24	Q3 24	Q4 24	Q1 25	Q2 25	Q3 25	Q4 25	Q1 26	Q2 26	LTM
Revenue	180	214	192	219	217	275	225	305	249	316	223	280	255	413	246	248	265	280	251	304	294	324	279	276	252	305	288	617	381	377	350	399	378	430	307	391	394	385	393	496	1,668
Cost of Revenue	35	35	40	40	36	39	44	43	39	49	45	46	42	46	47	45	43	43	41	53	50	54	55	58	51	54	58	63	61	70	59	61	63	62	49	49	52	46	62	98	257
Gross Profit	145	179	151	179	181	237	181	261	209	267	178	234	213	366	199	202	222	237	210	251	245	271	223	218	202	251	229	554	319	307	292	338	315	368	257	341	343	338	331	398	1,410
Research & Development	99	90	105	99	104	104	108	107	101	109	103	104	108	198	93	94	95	112	92	97	118	98	96	93	100	105	64	68	65	21	68	60	60	57	72	77	82	93	103	113	391
Selling, General & Administrative	91	97	102	109	100	111	118	138	129	141	51	155	149	154	46	49	49	46	45	53	48	147	49	55	56	160	49	58	42	24	54	48	48	48	49	50	56	101	109	63	329
Total Operating Expenses	206	202	222	224	220	231	243	261	246	267	254	270	267	376	236	236	233	268	227	246	264	268	250	252	262	271	240	273	230	129	248	228	210	205	244	248	254	280	380	380	1,293
Operating Income	-61	-24	-71	-45	-38	5.8	-62	-0.1	-37	0.0	-76	-36	-54	-9.9	-37	-34	-11	-31	-16	4.4	-20	2.4	-27	-34	-61	-21	-11	281	89	179	43	110	105	163	14	93	89	58	-48	18	117
Interest Expense	3.4	4.9	2.8	2.9	3.1	3.2	5.5	3.1	3.3	3.5	3.5	3.5	3.4	3.2	2.9	2.1	1.8	1.9	4.0	2.4	2.4	2.4	2.4	2.4	3.6	4.8	5.3	5.7	6.0	6.1	6.0	6.0	6.0	4.6	0.0	0.0	0.0	12	21	26	59
Pre-Tax Income	-65	-24	-73	-46	-36	11	-67	-24	-34	-1.7	-100	-40	-54	-2.6	-31	-26	2.2	-42	-19	5.7	-27	0.2	-45	-33	-67	-22	-11	282	93	182	47	117	110	170	25	105	101	60	-62	-1.9	97
Income Tax Expense	-2.7	-3.2	-3.7	-2.7	0.5	21	-4.5	8.2	0.6	8.0	-3.9	1.6	-1.0	2.8	7.3	3.7	2.3	1.0	3.8	3.3	2.5	-0.6	-9.1	-3.1	-3.4	6.6	0.7	2.7	1.2	-94	8.0	22	17	24	3.0	18	18	11	4.6	-2.4	31
Net Income	-63	-21	-69	-43	-36	-9.8	-63	-33	-34	-9.7	-96	-42	-53	-5.4	-39	-29	-0.1	-43	-22	2.4	-29	0.9	-36	-30	-64	-28	-42	237	48	113	37	91	92	147	22	87	83	49	-66	0.5	66
EBITDA	-38	5.2	-46	-18	-7.6	39	-36	4.5	-4.2	28	-77	-17	-30	21	-7.9	-3.3	25	-19	5.0	27	-4.7	24	-23	-11	-44	-7.8	13	307	117	207	61	129	123	181	33	113	109	77	-22	54	218

LTM = last twelve months (sum of the four most recent quarters).

Showing the most recent 40 periods — older statements are on file for this stock.

Data as of: September 23, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?

Income Statement

Cookie settings